Sidley represented BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, in a collaboration with Janssen Biotech, Inc., a Johnson & Johnson company.
This strategic collaboration combines the drug discovery, clinical development, and data science expertise from Johnson & Johnson with BigHat’s Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high-quality antibodies for multiple neuroscience therapeutic targets.
BigHat’s antibody design platform, Milliner™, integrates a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering platform, to engineer antibodies with more complex functions and better biophysical properties. This approach reduces the difficulty of designing antibodies and other therapeutic proteins to tackle conditions ranging from chronic illness to life-threatening disease, while also massively speeding up candidate discovery and validation.
The Sidley team was led by Alison Lehner (Emerging Companies and Venture Capital), Asher Rubin, and Collin Marshall (Technology and Life Sciences Transactions).
For additional information, please refer to the press release.
